CD47 and myelodysplastic syndrome: In 2019, combination of CD47 mAb magrolimab and azacitidine in the treatment of acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) showed excellent and sustainable efficacy with manageable hematological toxicity when the initial dose of 1 mg/kg was given one week before the treatment dose (10–30 mg/kg) [12].